于思源,王芳,冯志平
YU Siyuan,WANG Fang,FENG Zhiping

• 1:中山大学附属江门医院(江门市中心医院)药学部

摘要(Abstract)：

目的建立快捷的高效液相色谱-串联质谱法(HPLC-MS/MS)测定某院侵袭性真菌感染患者血浆中伏立康唑的谷浓度,并初步考察其有效谷浓度范围。方法以氯雷他定为内标,用乙腈直接蛋白沉淀的方法,色谱柱为ZORBAX Eclipse XDB-C18柱(50 mm×4.6 mm,1.8μm),流动相为乙腈—0.1%甲酸的10 mmol·L~(-1)甲酸铵水溶液(85∶15),流速为0.4 mL·min~(-1),正离子多反应监测(MRM)模式扫描分析,检测15例侵袭性真菌感染患者的伏立康唑谷浓度,并观察其临床疗效和不良反应。结果血浆中伏立康唑浓度的线性范围为0.01~10.00μg·m L~(-1)(r=0.999 2),定量下限为0.01μg·mL~(-1),提取回收率在94.94%~104.73%之间,日内、日间精密度相对标准偏差(RSD)均小于15%。患者体内伏立康唑的血药浓度为0.739~8.763μg·mL~(-1)。结论该方法快速、灵敏,适用于伏立康唑血药浓度监测。由于伏立康唑的个体间浓度差异大,对危重患者开展常规伏立康唑谷浓度监测有助于提高临床疗效,减少不良反应的发生。
OBJECTIVE To establish a simple and quick HPLC-MS/MS method for the determination of voriconazole trough concentration in patients with invasive fungal infection,and investigate the range of proper trough concentration in our hospital.METHODS The plasma procedure involved a single-step protein precipitation by acetonitrile,then chromatographed on a ZORBAX Eclipse XDB-C18( 50 mm×4.6 mm,1.8 μm) using a mobile phase composed of acetonitrile-0.1% formic acid in 10 mmol·L~(-1)ammonium formate( 85 ∶15) at a flow rate of 0.4 m L·min~(-1),with Loratadine as internal standard.The protonated ions of analytes were detected in positive ionization in multiple reaction monitoring( MRM) mode. The specificity,standard curve,lower limit of quantitation( LLOQ),precision,recovery rate as well as the matrix effect were investigated. The trough concentrations of voriconazole in 15 patients with invasive fungal infection were analyzed by this method.The efficacy and adverse drug reactions during the pharmacotherapy period were observed. RESULTS The calibration curve was linear over a concentration range of 0. 01~(-1)0. 00 μg·m L~(-1)( r = 0.999 2),the lower limit of quantitation was 0.01 μg·m L~(-1).The extraction recovery rates ranged from 94.94%~(-1)04.73%,intra-day and inter-day RSD were all less than 15%.The plasma concentrations of voriconazole in patients were 0.739-8.763 μg·m L~(-1). CONCLUSION The method is quick and sensitive. It is suitable for the concentration determination of voriconazole in patients. Because of the high concentration variability among patients,routine monitoring of voriconazole trough concentration for critical patients may help to increase the probability of achieving therapeutic efficacy and decrease adverse events.

关键词(KeyWords)： 伏立康唑;谷浓度;高效液相色谱-串联质谱
voriconazole;trough concentration;HPLC-MS/MS

Abstract:

Keywords:

基金项目(Foundation): 江门市科技计划项目(2015079)

作者(Author): 于思源,王芳,冯志平
YU Siyuan,WANG Fang,FENG Zhiping

参考文献(References)：

• [1]Sili U,Bilgin H,Masania R,et al.Successful treatment of an invasive fungal infection caused by Talaromyces sp.with voriconazole[J].Med Mycol Case Rep,2015,8:21-23.
• [2]Barreto J N,Beach C L,Wolf R C,et al.The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole[J].Am J Hematol,2013,88(4):283-288.
• [3]Hoenigl M,Duettmann W,Raggam R B,et al.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies[J].Antimicrob Agents Chemother,2013,57(7):3262-3267.
• [4]Kim S H,Lee D G,Kwon J C,et al.Clinical impact of cytochrome P450 2C19 genotype on the treatment of invasive aspergillosis under routine therapeutic drug monitoring of voriconazole in a korean population[J].Infect Chemother,2013,45(4):406-414.
• [5]Wang T,Zhu H,Sun J,et al.Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections[J].Int J Antimicrob Agents,2014,44(5):436-442.
• [6]Kim S H,Yim D S,Choi S M,et al.Voriconazole-related severe adverse events:clinical application of therapeutic drug monitoring in Korean patients[J].Int J Infect Dis,2011,15(11):753-758.
• [7]田洁,彭菲,张贵宁,等.我院伏立康唑致不良反应30例报告分析[J].中国药房,2015,24(17):2350-2352.
• [8]Park W B,Kim N H,Kim K H,et al.The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections:a randomized controlled trial[J].Clin Infect Dis,2012,55(8):1080-1087.
• [9]李娅杰,赵明,赵德恒,等.美国FDA关于抗菌药物疗效评价的考虑[J].中国临床药理学杂志,2008,24(4):379-381.
• [10]谢松梅,赵明,杨进波,等.我国抗菌药物临床疗效评价标准的思考与确定[J].中国临床药理学杂志,2008,24(5):466-468.
• [11]孟冬梅,陈文瑛,邓礼荷,等.体重与伏立康唑稳态血药谷浓度的相关性分析[J].今日药学,2014,24(4):232-233,239.
• [12]王超,张弋.RP-HPLC法测定肾移植术后患者血浆中伏立康唑的浓度[J].中国药房,2014,25(18):1668-1670.
• [13]曲彩红,周凤丽,黄建华,等.高效液相色谱-串联质谱法测定侵袭性真菌感染患者伏立康唑的血药浓度[J].中国医院药学杂志,2013,33(1):19-23.
• [14]杨源,郑国钢,藏恒昌.伏立康唑胶囊人体药代动力学及相对生物利用度研究[J].中国现代应用药学,2013,30(5):499-502.
• [15]冯仕银,雍小兰,杜晓琳,等.LC-MS/MS法测定人血浆及唾液中伏立康唑浓度[J].中国新药杂志,2012(16):1908-1911.
• [16]付双双,熊歆,段京莉,等.伏立康唑患者血药浓度的监测[J].中国临床药理学杂志,2013,29(8):622-624.
• [17]Ashbee H R,Barnes R A,Johnson E M,et al.Therapeutic drug monitoring(TDM)of antifungal agents:guidelines from the British Society for Medical Mycology[J].J Antimicrob Chemother,2014,69(5):1162-1176.
• [18]Zachary H,Elizabeth S D A,Geoffrey A W,et al.Voriconazole therapeutic drug monitoring[J].Antimicrob Agents Chemother,2014,3(3):270-271.
• [19]Lat A,Thompson G R.Update on the optimal use of voriconazole for invasive fungal infections[J].Infect Drug Resist,2011,4(4):43-53.
• [20]Suzuki Y,Tokimatsu I,Sato Y,et al.Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity[J].Clin Chim Acta,2013,424:119-122.
• [21]何杏莲,卢荣枝,赵春林.280例侵袭性真菌感染致病菌构成分布及药敏分析[J].今日药学,2014,24(9):682-683.